Rifaximin
Steatohepatitis
Bezmialem Vakif UniversitySmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Steatohepatitis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Alpha Tocopherol Aristotle University Of Thessaloniki | Phase 2 | B |
Epa-E Mochida Pharmaceutical Company, Ltd. | Phase 2 | B |
Spironolactone Aristotle University Of Thessaloniki | Phase 2 | B |
Metformin Austrian Breast & Colorectal Cancer Study Group | Phase 2 | CCC |
azd7503 AstraZeneca | Phase 1 | CC |
Ontamalimab Takeda | Phase 1 | NR |
Same molecule, other indications
Rifaximin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →